Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 215, Issue 1, Pages 17-23Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiw475
Keywords
burden of illness; children; respiratory syncytial virus; vaccines; antivirals
Categories
Funding
- Novavax
- Wyeth
- GlaxoSmithKline
- Academy of Finland
- European Scientific Working Group on Influenza
- Foundation for Pediatric Research in Finland
- Jenny and Antti Wihuri Foundation, Finland
Ask authors/readers for more resources
Background. Vaccines and antivirals against respiratory syncytial virus (RSV) are being developed, but there are scarce data on the full impact of RSV infection on outpatient children. Methods. We analyzed the burden of RSV illness in a prospective cohort study of children aged <= 13 years during 2 consecutive respiratory seasons in Turku, Finland (2231 child-seasons of follow-up). We examined the children and obtained nasal swabs for the detection of RSV during each respiratory illness. The parents filled out daily symptom diaries throughout the study. Results. Of 6001 medically attended respiratory infections, 302 (5%) were caused by RSV. Per 1000 children, the average annual RSV infection incidence rates among children aged < 3, 3-6, and 7-13 years were 275, 117, and 46 cases, respectively. In children aged < 3 years, acute otitis media developed in 58%, and 66% of children in this age group received antibiotics. The mean duration of RSV illness was longest (13.0 days) and the rate of parental work absenteeism was highest (136 days per 100 children with RSV illness) in children aged < 3 years. Conclusions. The burden of RSV is particularly great among outpatient children aged < 3 years. Young children are an important target group for the development of RSV vaccines and antivirals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available